Related Experiment Videos
Neuroprotective agents in acute ischemic stroke
1Department of Neurology, St. Stephen's Hospital, Tis Hazari, New Delhi.
Abstract:
The concept of neuroprotection relies on the principle that delayed neuronal injury occurs after ischemia. The phenomenon of the "ischemic cascade" has been described, and each step along this cascade provides a target for therapeutic intervention. A wide variety of drugs have been studied in humans. Ten classes of neuroprotective agents have reached phase III efficacy trials but have shown mixed results. They included calcium channel antagonists, NMDA receptor antagonists, lubeluzole, CDP-choline, the free radical scavenger tirilazad and ebselen, enlimomab, GABA agonist clomethiazole, the sodium channel antagonist fosphenytoin, magnesium, glycine site antagonist GV150526 and piracetam. Furthermore, the mechanisms that underlie the development of focal ischemic injury continue to be discovered, opening new therapeutic perspective for neuroprotection that might clinically be applicable in the future.
Insights
Neuroprotection aims to prevent delayed brain injury after ischemia by targeting the ischemic cascade. Despite extensive research and numerous drug trials, neuroprotective agents have yielded mixed results, highlighting the need for further investigation.
Area of Science:
- Neuroscience
- Pharmacology
- Neurology
Background:
- Delayed neuronal injury following ischemia is a key concept in neuroprotection.
- The "ischemic cascade" presents multiple therapeutic targets for intervention.
- Understanding these mechanisms is crucial for developing effective treatments.
Purpose of the Study:
- To review the therapeutic strategies and clinical trial outcomes for neuroprotection.
- To explore the ongoing discovery of mechanisms underlying focal ischemic injury.
- To identify future therapeutic perspectives for clinical neuroprotection.
Main Methods:
- Review of existing literature on neuroprotection and ischemic injury.
- Analysis of clinical trial data for various neuroprotective agents.
- Exploration of emerging research on the mechanisms of focal ischemia.
Main Results:
- Ten classes of neuroprotective agents have undergone Phase III efficacy trials.
- Clinical trial results for these agents have been mixed.
- Ongoing research continues to uncover new mechanisms of ischemic injury.
Conclusions:
- Neuroprotection strategies targeting the ischemic cascade have shown limited success to date.
- Further research into the underlying mechanisms of ischemic injury is essential.
- New therapeutic approaches for neuroprotection may emerge from continued scientific discovery.